Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool June 17, 2008 Brian Orelli	Change a Label, Change the Game For Teva Pharmaceutical, swapping the label on its Parkinson's drug, Azilect, could add hundreds of millions of dollars in sales per year.
The Motley Fool August 27, 2008 Brian Orelli	Teva Tells It Like It Is For Teva Pharmaceuticals, the details only confirmed the great initial report of the clinical trial success for its Parkinson's disease treatment Azilect.
The Motley Fool June 10, 2011 Brian Orelli	Abbott Picks Pumps Over Pills Treat Parkinson's disease, medical-device style.
The Motley Fool October 5, 2007 Brian Orelli	Merck's Next Blockbuster? Merck's cholesterol drug comes back from phase 2 testing with no side effects. Investors, take note.
The Motley Fool November 19, 2009 Brian Orelli	Pfizer's Generic Growth, With a Side of Sashimi A move into Japan isn't a bad idea, but it isn't going to save the company either.
The Motley Fool April 27, 2011 Brian Orelli	Don't Get Pumped Up About Pumping It In Medtronic and Eli Lilly team up against Parkinson's.
The Motley Fool November 27, 2006 Brian Lawler	Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs.
The Motley Fool December 28, 2006 Brian Lawler	Pliva's Late Christmas Gift to Barr Normally generic drug competitors, Barr Pharmaceuticals and Par Pharmaceutical Companies announced the launch of a generic version of GlaxoSmithKline's drug, Zofran. Investors, take note.
The Motley Fool January 29, 2010 Brian Orelli	How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years.
The Motley Fool May 18, 2009 Brian Orelli	Free Drugs! Pfizer's giving over 70 drugs away -- to people who have lost their jobs and health insurance recently and can show financial hardship.
The Motley Fool August 28, 2007 Brian Orelli	A Combination to Clear Your Head Merck and Schering-Plough get together again. But who can blame them? Their partnerships have been making both companies lots of money. Investors, take note.
The Motley Fool May 28, 2008 Brian Lawler	A Little-Noticed Drug Rejection The EU temporarily blocks Sanofi and Bristol-Myers' shot at extending a drug's lifespan.
The Motley Fool August 28, 2007 Brian Orelli	Teva Gets a Two-For Even for a maker of generic drugs, getting two FDA drug approvals in as many business days is a feat not often seen. Teva Pharmaceuticals managed to do it, though. Investors, take note.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool November 13, 2009 Brian Orelli	Questioning Pfizer's Integrity Pfizer's epilepsy drug Neurontin has had generic competition for a few years, but it's still plaguing the pharmaceutical giant.
The Motley Fool November 12, 2009 Brian Orelli	The Life-and-Death Situation That Isn't Branded-drug makers aren't playing fair because they refuse to sell samples to generic drug makers.
The Motley Fool December 29, 2009 Brian Orelli	Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others.
The Motley Fool September 30, 2010 Brian Orelli	Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers.
The Motley Fool December 30, 2008 Brian Orelli	2009's Generic Drugs: Who's at Risk The patent cliff is coming early for some drugmakers.
The Motley Fool August 23, 2004 Ben McClure	Rethinking Big Pharma Risk is knocking Big Pharma stocks down. They won't be getting up anytime soon. Competition, soaring R&D costs, shifting business models, and political meddling combine to make drug stocks a riskier place to invest.
The Motley Fool April 29, 2008 Brian Orelli	Merck's Recovery Flushed Down Merck's best hope at recovery fails approval by the FDA.
The Motley Fool September 23, 2008 Brian Orelli	Extended Look at an Extended-Release Drug The FDA is still investigating Teva's generic Wellbutrin XL.
The Motley Fool October 29, 2007 Brian Orelli	The Extended Release That Wasn't The FDA is investigating Teva's generic version of Wellbutrin XL. Investors, take note.
The Motley Fool April 24, 2009 Brian Orelli	Great Drugs Not Living Up to Their Potential How well a drug works is not the most important thing to consider when investing. Drugs that work don't always become blockbusters.
The Motley Fool June 22, 2006 Stephen D. Simpson	Merck Goes on the Attack Predator becomes prey in this latest twist in the generics game. Given how much the markets hate uncertainty, that could mean that big generic drug companies might go on sale for patient long-term investors.
The Motley Fool November 6, 2006 Brian Lawler	The Impending Verdict on Momenta The drug developer isn't willing to wait for potential legislation on generic drugs. Investors, take note.
The Motley Fool August 24, 2007 Brian Lawler	Flamel Under Fire Stocks fall when study fails to show drug's superiority. Investors, take note.
The Motley Fool December 9, 2009 Brian Orelli	Rising From the ASHes At the Super Bowl of blood cancer, the American Society of Hematology's annual conference, the presentations by drug companies made a few stocks catch on fire, while a couple burned up a little.
The Motley Fool February 20, 2009 Brian Orelli	Generic Synergies, Stellar Earnings Growth Mylan is working through its growing pains. The company doubled in size when it bought Merck KGaA's generic drug business, after it had already purchased Indian generic drugmaker Matrix Laboratories. In an instant, it became a global player.
The Motley Fool September 16, 2008 Brian Lawler	Pfizer Puts Safety First Increased FDA scrutiny may motivate the pharmaceutical's new drug-safety site.
The Motley Fool December 31, 2007 Brian Lawler	Big Pharma 2008 Forecast Roundup Investors, take a look at what 2008 has in store for big pharma.
The Motley Fool June 1, 2007 Brian Lawler	The Generic Cracks Open for Pfizer Pfizer loses a patent case over its top compound. The larger takeaway from the Lipitor legal saga is that investors always need to be aware of the strength of a drug company's patents throughout the world.
The Motley Fool March 15, 2007 Brian Lawler	It's All Good for Drugmakers With the whole drug industry growing so strongly, those looking for a safe place to park their investing dollars would be smart to take a look at some of the largest generic drugmakers.
The Motley Fool October 16, 2006 Brian Lawler	The Coming Generic Drug Boom Generic drugmakers are poised to profit from several key factors. Investors, take note.
The Motley Fool November 5, 2004 Roger Nusbaum	The Tale of Teva Generic drug companies like Teva may offer a smart way to own health care. However, the company's good fortune hit a bump when rival Andrx got pummeled with a bad earnings announcement, and Teva traded down in sympathy.
The Motley Fool November 24, 2009 Brian Orelli	4 Platform Drugmakers to Invest In Elan ... Alkermes... Flamel Technologies... etc.
The Motley Fool June 1, 2005 Rich Duprey	Able Labs Disabled The generic drug maker recalls its entire inventory over quality concerns. Its stock price cratered 75% the day after the announcement and has since fallen another 30% since then.
The Motley Fool June 30, 2009 Brian Orelli	A Cocktail for Drug Investors Drug cocktails aren't just for alchemists anymore. In many diseases they've become big business, and pharmaceutical investors would be smart to pay attention.
The Motley Fool December 1, 2009 Brian Orelli	Abbott Makes All the Right Moves Hot off its cholesterol win over Merck, Abbott Labs is playing it safe with another cholesterol drug, TriCor.
The Motley Fool January 31, 2007 Brian Lawler	Mylan on the Generic Attack Two new drug approvals for the generic drugmaker come in the midst of a changing regulatory environment. Investors, take note.
The Motley Fool May 28, 2004 Charly Travers	Don't Be a Biotech Gambler Stand on solid ground by learning to assess the value of future drug programs. Investing in biotechs -- rather than simply speculating in the sector -- requires a solid assessment of how much a company's drug programs could be worth.
The Motley Fool January 30, 2007 Brian Lawler	Pfizer Fights a Generic Threat Pfizer attempts to fend off a generic threat in Canada for its top drug. It's a trial worth paying attention to for its shareholders, as Canada does represent one of the larger pharmaceutical markets in the world.
The Motley Fool April 21, 2009 Brian Orelli	Reworking the Broken R&D Model When it comes to drug development, it's becoming increasingly clear that competition isn't always the best thing for the industry. Collaborations will help bring drugs to the market more cheaply.
The Motley Fool March 5, 2008 Brian Orelli	FDA (Indirectly) Thwacks Amylin The FDA's draft guidance puts a cloud of uncertainty over the makers of diabetes drugs.
The Motley Fool March 1, 2007 Brian Lawler	Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works.
The Motley Fool January 26, 2005 Stephen D. Simpson	The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities.
Chemistry World July 11, 2008 Manisha Lalloo	Side-effects study opens up new drug leads Existing drugs could be used to treat a broader range of diseases, according to scientists in Germany and Denmark, who have predicted drug targets by using side-effects data on medication labels.
The Motley Fool January 13, 2004 Jeff Hwang	Eon Labs' Potent Potential The generic drug maker's fourth-quarter estimates spiked higher.
The Motley Fool November 3, 2009 Brian Orelli	Amylin Scores a Hat Trick Amylin Pharmaceuticals got a triple dose of good news over the weekend.
Managed Care September 2006	Payers, Consumers Benefit as Patents Expire The generic drug market seems ready to explode, according to reports from IMS Health and the Generic Pharmaceuticals Association.